BNET Industries

Market Cap:$150.0B
Last Fiscal Year Sales:$48.4B
- Public
- US
Dow Jones Description
Taking care of you and your four-legged friends too! Pfizer Inc. (NYSE: PFE), based in New York, NY, discovers, develops, manufactures and sells prescription medications for humans and animals. Employing about 115,000 people, this $51.3 billion company operates in three segments: Human Health, Consumer Healthcare and Animal Health. Together, these segments cover treatments for diseases such as cardiovascular and metabolic diseases, medications for oral care, tobacco dependence, and products for prevention and treatment of diseases in livestock and pets.
Number of Employees 81,800
Peer Companies
NAICS Code Pharmaceutical Preparation Manufacturing: 325412
Recent Events
-
Can Roche Leave Genentech Alone?
-
Pfizer PFE Will Not Renew Ethical Distribution Agreement Term with MWI Veterinary Supply MWIV
-
Pfizer faces $103 million in Prempro damages [The Philadelphia Inquirer]
-
A 2nd Loss for Pfizer in Drug Suits
-
Pfizer acquires stem cell therapies assets of Axordia
-
Standpoint Raised Its FY10 Price Target on Pfizer PFE to $24
-
ImmunoVaccine signs exclusive licence deal with Pfizer
-
Pfizer Animal Health selects Bader Rutter as agency of record
-
FDA panel backs Pfizer's anti-infection vaccine for kids
-
Cash Just Kept On Piling Up, But It Looks Like The Spending Has Started
-
Goldman Sachs Said Pfizer PFE Best Positioned US Pharma in China
-
EDITORIAL: Difficult mix of business, science
-
Jury Awards $75 Million in Punitive Damages to Illinois Woman in Prempro Cancer Case
-
Sanofi-Aventis on hunt for Boston partners
-
Pfizer says in partnership deal with BMP in China
-
Pfizer Inc. PFE Says in Partnership Deal with BMP Sunstone in China
-
Still Enjoying Those Acquisitions, Pfizer?
-
Status Of Pfizer And Wyeth Research Facilities
-
Monsanto MON Agrees to Acquire Pfizer's PFE Chesterfield Village Research Center for $435M
News & Analysis
Filter by
license agreement and pfizer inc. - All News and Analysis
Helsinn and Pfizer Laboratories (Pty) Ltd Sign a License Agreement for the Marketing of Aloxi(R) in South Africa.
LUGANO, Switzerland and JOHANNESBURG, South Africa, March 10 /PRNewswire/ -- Helsinn Healthcare SA, and Pfizer Laboratories Pty Ltd, announce the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution ri LUGANO, Switzerland and JOHANNESBURG, South Africa, March...
Incyte to Host Conference Call Today to Discuss Collaborative Research and License Agreement with Pfizer for the Development and Commercialization of CCR2 Antagonists; Conference Call is Scheduled to Begin at 8:30 a.m. ET Today
WILMINGTON, Del. -- Incyte Corporation (Nasdaq:INCY) announced that it will host a conference call at 8:30 am ET today to discuss its collaborative research and license agreement with Pfizer for the development and commercialization of CCR2 antagonists. A copy of the press release, also released today, can be accessed at...
Pfizer and Incyte Enter Collaborative Research and License Agreement for the Development and Commercialization of CCR2 Antagonists
NEW YORK & WILMINGTON, Del. -- Incyte Corporation (NASDAQ:INCY):
Pfizer Inc. (Active Pharmaceutical Ingredient Watch).(seeks to terminate license agreement with Novo Nordisk )(Brief Article)
NOVO NORDISK A/S reports that Pfizer Inc. has attempted to terminate the license agreement under which Pfizer markets Novo Nordisk's portfolio of hormone replacement therapy products, Activella and Vagifem, in the US. In 2002, Novo Nordisk gained a NOVO NORDISK A/S reports that Pfizer...
Inhale Therapeutic Systems and Pfizer Inc Enter Into Pulmonary Insulin Product Development and License Agreement
PALO ALTO, Calif.--HealthWire--Jan. 19, 1995--Inhale Therapeutic Systems (Nasdaq:INHL) announced today that it has signed an agreement with Pfizer Inc (NYSE:PFE) to collaborate on the development of insulin products using Inhale's non-invasive pulmonary drug delivery system for macromolecules.
- 1
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
